Intellia Therapeutics Inc.
Rating
Updated: Aug 10, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered...
Latest News
8 days ago · seekingalpha.com
Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptIntellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
18 days ago · globenewswire.com
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points $75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points
2 months ago · zacks.com
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron RevenuesIntellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
2 months ago · marketbeat.com
Intellia Therapeutics Q2 Earnings Call HighlightsIntellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.
2 months ago · seekingalpha.com
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call TranscriptIntellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
2 months ago · zacks.com
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue EstimatesIntellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.
2 months ago · globenewswire.com
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business UpdatesCAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates.
2 months ago · defenseworld.net
Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLAAmova Asset Management Americas Inc. cut its position in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 10.0% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,973,061 shares of the company's stock after selling 219,400 shares during the quarter. Amova Asset Management
3 months ago · zacks.com
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
3 months ago · fool.com
This Stock Is Up 58% This Year. Is It too Late to Buy?There could be additional catalysts for this drugmaker over the next year.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NTLA